Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hypercalcemia in bronchogenic carcinoma].

P Zatloukal, F Macholda, O Mĕricka

    Sbornik Lekarsky
    |March 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Hypercalcemia affects over 10% of patients with bronchogenic carcinoma. Epidermoid carcinoma showed the highest rate of hypercalcemia, though differences between major types were not statistically significant.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    EFFICACY OF THE ALGORITHMIC STEP-UP APPROACH OF INTERVENTIONAL TREATMENT OF PATIENTS WITH ACUTE NECROTIZING PANCREATITIS.

    Georgian medical news·2022
    Same author

    [The TULUNG clinical registry].

    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2012
    Same author

    A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2011
    Same author

    [TARCEVA Clinical Registry].

    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2010
    Same author

    A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

    Annals of oncology : official journal of the European Society for Medical Oncology·2010
    Same author

    Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).

    Annals of oncology : official journal of the European Society for Medical Oncology·2010

    Area of Science:

    • Oncology
    • Internal Medicine
    • Pulmonology